ALSense

ALSense is developing an aptamer-based blood biosensor for the early and specific diagnosis of amyotrophic lateral sclerosis (ALS). Our platform targets a panel of three biomarkers (neurofilaments and two TDP-43-related cryptic peptides), offering high sensitivity and rapid turnaround. Our main activities include biomarker validation, aptamer engineering, device prototyping and clinical translation. ALSense aims to serve neurologists, hospitals and health systems seeking faster, fairer and more accessible ALS diagnostics.